Daño hepático inducido por medicamentos: relación entre el índice R y la histopatología

Daño hepático inducido por medicamentos: relación entre el índice R y la histopatología

Resumen: Introducción y objetivo: El daño hepático inducido por medicamentos (DILI, por sus siglas en inglés), es un diagnóstico basado en la exclusión de potenciales hepatopatías, y que se consolida, estableciendo la causalidad entre una sustancia potencialmente hepatotóxica y la alteración del pe...

Full description

Bibliographic Details
Main Authors:	O.M. Ardila-Suárez, L. Oriz-Benjumea, A.A. Arteta, L.G. Guevara-Casallas
Format:	Article
Language:	Spanish
Published:	Elsevier 2023-01-01
Series:	Revista de Gastroenterología de México
Subjects:	DILI Liver injury Efavirenz Colombia Moringa
Online Access:	http://www.sciencedirect.com/science/article/pii/S0375090621001282

Similar Items

Drug-induced liver injury: Relation between the R ratio and histopathology
by: O.M. Ardila-Suárez, et al.
Published: (2023-01-01)

Respuesta a Sánchez-Luque et al.: «El método de evaluación de causalidad de hepatotoxicidad de Roussel-Uclaf (RUCAM) en el contexto de sospecha diagnóstica de daño hepático inducido por medicamentos DILI: es aún vigente?»
by: O.M. Ardila-Suárez, et al.
Published: (2023-10-01)

Answer to Sánchez-Luque et al. regarding “The Roussel-Uclaf hepatotoxicity causality assessment method in the context of diagnostic suspicion of drug-induced liver damage: Is it still valid?”
by: O.M. Ardila-Suárez, et al.
Published: (2023-10-01)

Mechanisms of cell death pathway activation following drug-induced inhibition of mitochondrial complex I
by: Naoki Imaizumi, et al.
Published: (2015-04-01)

Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes
by: Kang Kwang Lee, et al.
Published: (2014-01-01)

BASIN DİLİ ÜZERİNE BAZI DİKKATLER
by: ersin özarslan
Published: (2014-02-01)

BASIN DİLİ ÜZERİNE BAZI DİKKATLER
by: ersin özarslan
Published: (2014-02-01)

BASIN DİLİ ÜZERİNE BAZI DİKKATLER
by: ersin özarslan
Published: (2014-02-01)

Editorial: Therapeutic strategies for drug-induced liver injury: Review of the current literature
by: Mercedes Robles-Díaz, et al.
Published: (2022-11-01)

A Case Series of Efavirenz Induced Gynaecomastia
by: Charu Jain , Neha Sharma , Uma Advani , Lokendra Sharma , Munesh Kumar , Monica Jain
Published: (2023-08-01)

Herbal slimming formulations or remedies interact with antiretroviral therapy
by: Mukesh Dheda
Published: (2017-04-01)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe
by: Sandra Shawarira-Bote, et al.
Published: (2019-08-01)

Influence of milling process on efavirenz solubility
by: Erizal Zaini, et al.
Published: (2017-01-01)

Como pesquisar o perfil patentário de um fármaco: o caso Efavirenz How to determine the patent profile of a drug: a case study of Efavirenz
by: Jaqueline Mendes Soares, et al.
Published: (2010-01-01)

Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
by: Smita Prakash Kakad, et al.
Published: (2021-01-01)

Development and validation of a HPLC analytical assay method for efavirenz tablets: a medicine for HIV infections
by: Osnir de Sá Viana, et al.
Published: (2011-03-01)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
by: Manoranjenni Chetty, et al.
Published: (2018-03-01)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
by: Adrian Curran, et al.
Published: (2020-04-01)

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
by: Wang T, et al.
Published: (2023-07-01)

Efavirenz challenge in patients with nevirapine induced Stevens-Johnson Syndrome
by: Thandekile C. Manzini, et al.
Published: (2016-12-01)

Safety, strength and simplicity of efavirenz in pregnancy
by: Prinitha Pillay, et al.
Published: (2012-03-01)

The man with bilateral nipple pain
by: Hong Hooi Chuen, et al.
Published: (2013-12-01)

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis
by: Nathan W. Cummins, et al.
Published: (2015-07-01)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
by: Selemani Saidi Sungi, et al.
Published: (2018-10-01)

A sensitive and robust lc-ms/ms method with monolithic column and electrospray ionization for the quantitation of efavirenz in human plasma: application to a bioequivalence study
by: Danilo Cesar Galindo Bedor, et al.
Published: (2011-01-01)

El método de evaluación de causalidad de hepatotoxicidad de Roussel-Uclaf en el contexto de sospecha diagnóstica de daño hepático inducido por medicamentos: ¿es aún vigente?
by: C.B. Sánchez Luque
Published: (2023-10-01)

Beden Dili Çalışmalarında Unutulan Bir Eser: “Yüz İfadelerinin Tefsiri Hakkında Tecrübi Bir Tetkik”
by: Ozan İpek
Published: (2017-07-01)

FDA Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses In Vitro
by: Michal Stefanik, et al.
Published: (2020-06-01)

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
by: Supphachoke Khemla, et al.
Published: (2023-04-01)

Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa
by: Lyneshree Munsami, et al.
Published: (2023-01-01)

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART
by: Jaime H. Vera, et al.
Published: (2019-08-01)

Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC
by: Arun Ramaswamy, et al.
Published: (2018-02-01)

Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin
by: Nina Mariana, et al.
Published: (2016-09-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny
Published: (2009-12-01)

Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS
by: Anggriani Yusi, et al.
Published: (2019-08-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny Yenny
Published: (2016-02-01)

Atripla<sup>R</sup>/anti-TB combination in TB/HIV patients. Drug in focus
by: Semvua Hadija H, et al.
Published: (2011-11-01)

Efavirenz poisoning in a 12 year old HIV negative African boy
by: Rose Nazziwa, et al.
Published: (2012-07-01)

1-(2-Amino-5-chlorophenyl)-2,2,2-trifluoroethan-1-one
by: Jie Gao, et al.
Published: (2019-07-01)